Vertex Pharmaceuticals Incorporated (VRTX) News
Filter VRTX News Items
VRTX News Results
|Loading, please wait...|
VRTX News Highlights
- For VRTX, its 30 day story count is now at 20.
- Over the past 20 days, the trend for VRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- GENE, VIVO and CF are the most mentioned tickers in articles about VRTX.
Latest VRTX News From Around the Web
Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.
Robert W. Baird Stick to Their Buy Rating for Vertex Pharmaceuticals
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $220.16, marking a +0.45% move from the previous day.
The relationship between Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) is taking another big step forward. On Tuesday morning, the collaboration partners amended their agreement regarding CTX001 in a way that places more risk on Vertex's shoulders. CRISPR Therapeutics and Vertex had already agreed to co-commercialize and co-develop CTX001, an experimental gene therapy for patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT).
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CRISPR to receive $900 million upfront payment with potential for additional $200 million milestone payment upon CTX001 regulatory approval - BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 20, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced that the companies have amended their collaboration agreement to develop, manufacture and commercialize CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease (S...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
For the past 12 years, growth stocks have run absolute circles around value stocks. Borrowing rates have continued to push lower and, for much of the past 12 years, the Federal Reserve has maintained a dovish stance with regard to monetary policy. In short, growth stocks have had cheap access to capital with which to innovate, hire, and even acquire other businesses.
In this video from Motley Fool Live, recorded on March 22, Fool.com contributors Brian Orelli and Keith Speights discuss the prospects for Revolution Health Acquisition Corp. (NASDAQ: REVH.U). The healthcare-focused special purpose acquisition company (SPAC) is sponsored by ARCH Ventures and General Catalyst and has some solid leadership at the helm, including former CEO of Vertex (NASDAQ: VRTX) Jeffrey Leiden who serves as the SPAC's chairman.
When Cathie Wood talks, investors listen. The founder of Ark Invest has successfully predicted stock market stars -- one of her top holdings is Tesla. Now, here's some great news for all of us who want to follow this investment superstar's lead: Right now, you can buy three of the biggest holdings in her Ark Genomic Revolution ETF at a bargain.
The Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Is Up 155% And Shareholders Are Boasting About It
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Everyone knows that ARK Invest CEO Cathie Wood is a huge fan of Tesla (NASDAQ: TSLA). In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli identify four healthcare stocks that are among Wood's top holdings that just might deliver bigger gains than Tesla.